Pro-Dex (PDEX) Sets New 12-Month High at $17.00

Pro-Dex Inc (NASDAQ:PDEX) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $17.00 and last traded at $15.44, with a volume of 37300 shares traded. The stock had previously closed at $15.25.

Separately, ValuEngine upgraded shares of Pro-Dex from a “hold” rating to a “buy” rating in a research report on Monday, February 4th.

The stock has a market capitalization of $61.44 million, a PE ratio of 27.98 and a beta of 1.02. The company has a current ratio of 7.78, a quick ratio of 6.08 and a debt-to-equity ratio of 0.25.

In related news, CFO Alisha Charlton sold 2,114 shares of the firm’s stock in a transaction dated Wednesday, February 13th. The shares were sold at an average price of $15.81, for a total transaction of $33,422.34. Following the completion of the sale, the chief financial officer now directly owns 4,778 shares in the company, valued at $75,540.18. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Raymond E. Cabillot sold 20,749 shares of Pro-Dex stock in a transaction dated Tuesday, February 12th. The shares were sold at an average price of $15.65, for a total transaction of $324,721.85. Following the sale, the director now owns 95,613 shares of the company’s stock, valued at $1,496,343.45. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 26,763 shares of company stock valued at $416,062. 41.70% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in PDEX. FNY Investment Advisers LLC acquired a new stake in shares of Pro-Dex during the fourth quarter valued at about $131,000. BlackRock Inc. increased its position in shares of Pro-Dex by 49.2% during the fourth quarter. BlackRock Inc. now owns 12,369 shares of the medical instruments supplier’s stock valued at $150,000 after acquiring an additional 4,078 shares during the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of Pro-Dex during the fourth quarter valued at about $183,000. Acadian Asset Management LLC increased its position in shares of Pro-Dex by 42.6% during the fourth quarter. Acadian Asset Management LLC now owns 41,313 shares of the medical instruments supplier’s stock valued at $499,000 after acquiring an additional 12,337 shares during the last quarter. Finally, Vanguard Group Inc increased its position in shares of Pro-Dex by 50.8% during the third quarter. Vanguard Group Inc now owns 49,399 shares of the medical instruments supplier’s stock valued at $514,000 after acquiring an additional 16,644 shares during the last quarter. Institutional investors and hedge funds own 11.46% of the company’s stock.

WARNING: “Pro-Dex (PDEX) Sets New 12-Month High at $17.00” was published by WKRB News and is owned by of WKRB News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.wkrb13.com/2019/04/16/pro-dex-pdex-sets-new-12-month-high-at-17-00.html.

Pro-Dex Company Profile (NASDAQ:PDEX)

Pro-Dex, Inc, together with its subsidiaries, designs, develops, and manufactures powered surgical instruments, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and shavers and machined parts. In addition, it provides engineering, and quality and regulatory consulting services.

Featured Story: What is Net Asset Value (NAV)?

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.